Timothy Chan

Timothy Chan at Cleveland Clinic is a leader in cancer immunogenomics and the intersection of radiotherapy and immunology. He validated tumor mutational burden (TMB) as a biomarker for immunotherapy response and has made major contributions to understanding the abscopal effect — the regression of non-irradiated tumors following local radiation, mediated by immune activation. His work on neoantigen-based vaccines and radiation-immune combination strategies is highly influential.